| pubmed-article:8957747 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C0037663 | lld:lifeskim |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C0202220 | lld:lifeskim |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8957747 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:8957747 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8957747 | pubmed:dateCreated | 1997-3-6 | lld:pubmed |
| pubmed-article:8957747 | pubmed:abstractText | Due to a lack of longitudinal data the precise effect of long-term corticosteroid treatment on serum levels of the anabolic hormones Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) is unknown. Therefore, we prospectively followed GH and IGF-1 levels over a six month period in 18 euthyroid patients with Graves' ophthalmopathy. Ten patients were treated with a three month course of prednisone; eight patients receiving retrobulbar irradiation served as controls. Baseline serum GH and IGF-1 levels were similar in both groups. Whereas no changes were seen in controls, prednisone induced a rapid increase in serum IGF-1 levels, which was sustained during the entire treatment period: 18.2 +/- 5.2 at baseline vs 24.1 +/- 6.7 nmol/l after 12 weeks of treatment (p < 0.001). After discontinuation of prednisone IGF-1 returned to baseline levels. Basal GH levels were frequently undetectable, but during treatment GH values were lower in the prednisone group (median of detectable values 4.0 mU/L [range 2.0-26.0]) than in controls (11.8 [2.8-44.0]; p < 0.01). In conclusion, long-term prednisone treatment is associated with suppressed GH levels and with an increase in total IGF-1 levels. This suggests that prednisone can disrupt the GH/IGF 1 axis. | lld:pubmed |
| pubmed-article:8957747 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8957747 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8957747 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8957747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8957747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8957747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8957747 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8957747 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8957747 | pubmed:issn | 0391-4097 | lld:pubmed |
| pubmed-article:8957747 | pubmed:author | pubmed-author:EndersBB | lld:pubmed |
| pubmed-article:8957747 | pubmed:author | pubmed-author:WiersingaW... | lld:pubmed |
| pubmed-article:8957747 | pubmed:author | pubmed-author:OostingHH | lld:pubmed |
| pubmed-article:8957747 | pubmed:author | pubmed-author:PrummelM FMF | lld:pubmed |
| pubmed-article:8957747 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8957747 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:8957747 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8957747 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8957747 | pubmed:pagination | 620-3 | lld:pubmed |
| pubmed-article:8957747 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:meshHeading | pubmed-meshheading:8957747-... | lld:pubmed |
| pubmed-article:8957747 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8957747 | pubmed:articleTitle | The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1. | lld:pubmed |
| pubmed-article:8957747 | pubmed:affiliation | Department of Endocrinology, University of Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:8957747 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8957747 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8957747 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8957747 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8957747 | lld:pubmed |
